To include your compound in the COVID-19 Resource Center, submit it here.

RedHill's Bekinda meets in Phase II for IBS-D

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) reported top-line data from a Phase II trial in 126 patients with irritable bowel syndrome with diarrhea (IBS-D) showing that once-daily

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE